ArticleJournal of endocrinological investigation2026
Management of patients with hypoparathyroidism: a Delphi consensus analysis.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic hypoparathyroidism is a rare endocrine disorder characterized by parathyroid hormone (PTH) deficiency and associated with substantial clinical and therapeutic challenges. Despite conventional therapy and the off-label use of teriparatide, important unmet needs persist regarding metabolic control, prevention of long-term complications, and health-related quality of life (HRQoL). Although recent international and national guidelines have updated recommendations on chronic hypoparathyroidism management, relevant uncertainties and heterogeneity remain in real-world practice, particularly concerning the identification of patients not adequately controlled with conventional therapy, the therapeutic positioning and timing of PTH replacement therapy, monitoring strategies, and the implementation of structured care pathways. This study aimed to assess the level of expert consensus on the current management of hypoparathyroidism in Italy and to identify key gaps and potential areas for therapeutic and organizational improvement.
methodsA consensus survey was conducted using the Delphi method in two rounds. The Steering Committee defined 41 statements on the management of hypoparathyroidism, which were submitted to 20 expert clinicians via an online survey. Consensus was considered to have been reached with ≥ 70% of responses 4-5 (Likert scale 1-5).
resultsThe completion rate was 100%. Consensus was reached for 39/41 statements (95.1%). Experts highlighted the limitations of conventional therapy and the off-label use of teriparatide, recognizing the impact of the disease on quality of life and the need for care pathways. The need for hormone replacement therapy was also emphasized, together with the importance of structured monitoring and multidisciplinary follow-up.
conclusionChronic hypoparathyroidism remains a clinically challenging condition with significant unmet needs. This Italian Delphi consensus complements recent international and national guidelines by providing expert-driven insights on real-world implementation, therapeutic positioning, monitoring, and care pathway development within the Italian healthcare context, supporting the need to introduce hormone replacement therapy and improve multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.